Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 22, 2015, Pages 6955-6960

  Yen, Hsin Yung ^a,b   Liu, Ying Chih ^b   Chen, Nai Yu ^b,c   Tsai, Chia Feng ^a,d   Wang, Yi Ting ^a,d,e   Chen, Yu Ju ^d   Hsu, Tsui Ling ^b   Yang, Pan Chyr ^f   Wong, Chi Huey ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d INSTITUTE OF CHEMISTRY   (Taiwan)

^e ACADEMIA SINICA   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Dimerization; Gefitinib; Glycosylation; Lung cancer; Tyrosin kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MUTANT PROTEIN; PHOSPHOSERINE; PHOSPHOTHREONINE; PROTEIN TYROSINE KINASE; EGFR PROTEIN, HUMAN; ENZYME INHIBITOR; PROTEIN BINDING; QUINAZOLINE DERIVATIVE; SIALIDASE;

ARTICLE; AUTOPHOSPHORYLATION; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; DIMERIZATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIALYLATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; DRUG EFFECTS; GENETICS; METABOLISM; MISSENSE MUTATION; PHOSPHORYLATION; TUMOR CELL LINE;

CELL LINE, TUMOR; DIMERIZATION; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MUTATION, MISSENSE; NEURAMINIDASE; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84930638381     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1507329112     Document Type: Article

References (47)

1. De Luca A, et al. (2008) The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214(3):559-567.
2. Dawson JP, et al. (2005) Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol 25(17):7734-7742.
3. Ferguson KM, et al. (2003) EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11(2):507-517.
4. Garrett TP, et al. (2002) Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110(6):763-773.
5. Lemmon MA (2009) Ligand-induced ErbB receptor dimerization. Exp Cell Res 315(4):638-648.
6. Ogiso H, et al. (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110(6):775-787.
7. Ferguson KM (2008) Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys 37:353-373.
8. Citri A, Yarden Y (2006) EGF-ERBB signalling: Towards the systems level. Nat Rev Mol Cell Biol 7(7):505-516.
9. Morandell S, Stasyk T, Skvortsov S, Ascher S, Huber LA (2008) Quantitative proteomics and phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signaling network. Proteomics 8(21):4383-4401.
10. Mitsudomi T, Yatabe Y (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 277(2):301-308.
11. Sharma SV, Settleman J (2009) ErbBs in lung cancer. Exp Cell Res 315(4):557-571.
12. Lynch TJ, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129-2139.
13. Paez JG, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304(5676):1497-1500.
14. Pao W, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(36):13306-13311.
15. Yun CH, et al. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105(6):2070-2075.
16. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7(3):169-181.
17. Pao W, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73.
18. Lau KS, et al. (2007) Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 129(1):123-134.
19. Yokoe S, et al. (2007) The Asn418-linked N-glycan of ErbB3 plays a crucial role in preventing spontaneous heterodimerization and tumor promotion. Cancer Res 67(5):1935-1942.
20. Whitson KB, et al. (2005) Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor. Biochemistry 44(45):14920-14931.
21. Tsuda T, Ikeda Y, Taniguchi N (2000) The Asn-420-linked sugar chain in human epidermal growth factor receptor suppresses ligand-independent spontaneous oligomerization. Possible role of a specific sugar chain in controllable receptor activation. J Biol Chem 275(29):21988-21994.
22. Li W, et al. (2006) Down-regulation of trypsinogen expression is associated with growth retardation in alpha1,6-fucosyltransferase-deficient mice: Attenuation of proteinase-activated receptor 2 activity. Glycobiology 16(10):1007-1019.
23. Wang X, et al. (2006) Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J Biol Chem 281(5):2572-2577.
24. Liu YC, et al. (2011) Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc Natl Acad Sci USA 108(28):11332-11337.
25. Odaka M, Kohda D, Lax I, Schlessinger J, Inagaki F (1997) Ligand-binding enhances the affinity of dimerization of the extracellular domain of the epidermal growth factor receptor. J Biochem 122(1):116-121.
26. Ferguson KM, Darling PJ, Mohan MJ, Macatee TL, Lemmon MA (2000) Extracellular domains drive homo- but not hetero-dimerization of erbB receptors. EMBO J 19(17):4632-4643.
27. Soderquist AM, Carpenter G (1984) Glycosylation of the epidermal growth factor receptor in A-431 cells. The contribution of carbohydrate to receptor function. J Biol Chem 259(20):12586-12594.
28. Sanders JM, Wampole ME, Thakur ML, Wickstrom E (2013) Molecular determinants of epidermal growth factor binding: A molecular dynamics study. PLoS ONE 8(1):e54136.
29. Yun CH, et al. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11(3):217-227.
30. Wang Z, et al. (2011) Mechanistic insights into the activation of oncogenic forms of EGF receptor. Nat Struct Mol Biol 18(12):1388-1393.
31. Shan Y, et al. (2012) Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell 149(4):860-870.
32. Rillahan CD, et al. (2012) Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. Nat Chem Biol 8(7):661-668.
33. Gajiwala KS, et al. (2013) Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. Structure 21(2):209-219.
34. Kim Y, et al. (2012) Temporal resolution of autophosphorylation for normal and oncogenic forms of EGFR and differential effects of gefitinib. Biochemistry 51(25):5212-5222.
35. Matsushita T, et al. (2013) Site-specific conformational alteration induced by sialylation of MUC1 tandem repeating glycopeptides at an epitope region for the anti-KL-6 monoclonal antibody. Biochemistry 52(2):402-414.
36. Hornbeck PV, et al. (2015) PhosphoSitePlus, 2014: Mutations, PTMs and recalibrations. Nucleic Acids Res 43(Database issue):D512-D520.
37. Coskun Ü, Grzybek M, Drechsel D, Simons K (2011) Regulation of human EGF receptor by lipids. Proc Natl Acad Sci USA 108(22):9044-9048.
38. Merlin J, et al. (2011) Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells. Oncogene 30(22):2514-2525.
39. Zhuo Y, Bellis SL (2011) Emerging role of alpha2,6-sialic acid as a negative regulator of galectin binding and function. J Biol Chem 286(8):5935-5941.
40. Saito T, et al. (2004) Differential activation of epidermal growth factor (EGF) receptor downstream signaling pathways by betacellulin and EGF. Endocrinology 145(9):4232-4243.
41. Batzer AG, Rotin D, Ureña JM, Skolnik EY, Schlessinger J (1994) Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol 14(8):5192-5201.
42. Rozakis-Adcock M, et al. (1992) Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature 360(6405):689-692.
43. Zimmer S, et al. (2009) Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling. J Cancer Res Clin Oncol 135(5):723-730.
44. Wang F, et al. (2012) Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR. J Exp Clin Cancer Res 31:65-74.
45. Song Y, Aglipay JA, Bernstein JD, Goswami S, Stanley P (2010) The bisecting GlcNAc on N-glycans inhibits growth factor signaling and retards mammary tumor progression. Cancer Res 70(8):3361-3371.
46. Brugger W, Thomas M (2012) EGFR-TKI resistant non-small cell lung cancer (NSCLC): New developments and implications for future treatment. Lung Cancer 77(1):2-8.
47. Chu YW, et al. (1997) Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 17(3):353-360.